Alpha-Lipoic Acid as a Means of Influence on Systemic Inflammation in Type 2 Diabetes Mellitus Patients with Prior Myocardial Infarction

Abstract

Patients with combined coronary heart disease and diabetes mellitus make up a growing segment of the population and require a com¬prehensive treatment approach. Patients with concurrent diabetes mellitus and coronary heart disease have a worse projection. Under these conditions, the incidence of recurrent myocardial infarction, early disability due to complications, and the risk of coronary death are increased. Therefore, the priority task is to find ways to optimize drug treatment of this category of patients, taking into account the impact of drugs on the pathogenetic links of coronary heart disease progression and the development of cardiovascular complications. One hundred twelve people were examined in the research. The patients had type 2 diabetes with a history of non-Q-myocardial infarction receiving oral antidiabetic therapy and basic therapy, including an ACE inhibitor, a β-blocker, a statin, and an antiplatelet agent. Analysis of the investigated parameters in the leading group after receiving alpha-lipoic acid for 4 months showed a significant decrease in the concentration of C-Reactive Protein, IL-6 and TNF-α. According to the results of our research, taking alpha-lipoic acid for 4 months in patients with type 2 diabetes who underwent non-Q-myocardial infarction reduced the activity of systemic inflammation and did not significantly affect the content of anti-inflammatory IL-10 in patients. In light of the above, it is of interest to administer alpha-lipoic acid to these patients, considering the positive effects of the agent such as antioxidant properties, vasorelaxation, positive metabolic profile, as well as an anti-inflammatory potential.

Ischemic-Postconditioning Improves Myocardial Injury and Fibrosis Following Ischemia/Reperfusion Injury in Diabetic Rats Pretreated with Alpha-Lipoic Acid

“…ALA has other beneficial effects such as vasorelaxation, a positive metabolic profile as well as an anti-inflammatory potential. 12 Additionally, according to the previous study, pretreatment of diabetic rats with ALA reestablished the infarct size-limiting effect of Post via regulating autophagy and improving mitochondrial function. 28 Therefore, it is inferred that the reduction of cardiac fibrosis can be attributed to both the recovery of cardiac autophagy and mitochondrial function, which improves the function of the heart.…”

“…Moreover, this compound is effective in I/R hearts in different ways including vasorelaxation, positive metabolic profile, and anti-apoptotic and antiinflammatory features. 12 It has been shown that ALA has also positive effects on the prevention and treatment of diabetes, 13 and preserves the heart from diabetic cardiomyopathy. 14 It seems that ALA can be more effective when it is used with another intervention.…”

Effect of Modified Diets Pancreatic Oxidative Markers in Streptozotocin-Induced Diabetic Wistar rats Following the Administration of Alpha Lipoic Acid

“…Intervention with HPD + ALA + MFM significantly increases the SOD, CAT and GSH levels in diabetic rats, which were significantly decreased in diabetic rats fed with HFD + ALA + MFM as well as in HCD + ALA + MFM respectively when compared to the diabetic rats fed with rat chaw, ALA and metformin. Alpha-lipoic acid (ALA) is thought to be the most successful antioxidant in clinical trials (Bobe et al, 2020;Altunina, Lizogub and Bondarchuk, 2020;Viana et al, 2022;Najafi et al, 2022;Al Mosawi, 2023). It is a natural compound with diverse biochemical functions, had been reported to acts as a metal chelator, regenerates endogenous antioxidants such as vitamins C and E, oxidizes glutathione within the cell (Maciejczyk et al, 2022), and is a modulator of the signalling transduction of several pathways (Capece et al, 2022;Capece et al, 2023).…”

Inflammation in Coronary Atherosclerosis: Insights into Pathogenesis and Therapeutic Potential of Anti-Inflammatory Drugs

“…The study aimed to evaluate the impact of ALA supplementation on inflammatory markers. After a 4-month period, researchers observed that ALA supplementation was associated with a significant decrease in the levels of CRP, IL-6, and TNF-alpha when compared to the placebo group [ 33 ].…”